Overview

• The company closed its acquisition of European digital health platform Zava in July to extend its telehealth offerings into Canada and Europe.
• Hims & Hers will introduce a Health Canada-approved generic semaglutide once Novo Nordisk’s Canadian patent officially expires in January.
• It is collaborating with an approved partner to ensure full compliance with Canadian regulations before bringing the drug to market.
• Following the announcement, Hims & Hers shares rose nearly 6%, reflecting investor confidence in its digital health expansion.
• Rival Sandoz has already filed for Health Canada approval of a generic semaglutide, signaling an intensifying competitive landscape.